Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

NCT00810758 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: PF-04878691 3mg
DRUG: PF-04878691 6mg
DRUG: PF-04878691 9mg

Sponsor

Pfizer